<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Remicade; Infliximab: rheumatic diseases" /><meta name="IX" content="Remicade; Infliximab: rheumatic diseases" /><title>Remicade®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="128235.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="128235.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=128235.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5288.htm">10.1.3 Drugs that suppress the rheumatic disease process</a> &gt; <a href="202659.htm">Cytokine modulators</a> &gt; <a href="128234.htm">INFLIXIMAB</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="212247.htm" title="Previous: GOLIMUMAB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="129937.htm" title="Next: RITUXIMAB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301005.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Disease-modifying Antirheumatic Drugs 92:36</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/9898-g.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Infliximab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: I &gt; Interactions of Infliximab</p></div></li></ul><ul><li><h3>British National Formulary (8)</h3></li><li><a href="100022.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory bowel disease</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="128210.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cytokine modulators</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response</p></div></li><li><a href="128211.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">INFLIXIMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response &gt; Cytokine modulators</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22infliximab%22%22infliximab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (8)</a></li></ul><ul><li><h3>BNF for Children (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/100022.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Inflammatory bowel disease</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/128210.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cytokine modulators</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/128211.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">INFLIXIMAB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 1 Gastro-intestinal system &gt; 1.5 Chronic bowel disorders &gt; 1.5.3 Drugs affecting the immune response &gt; Cytokine modulators</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22infliximab%22%22infliximab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/I04-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; I</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/9898-g.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Analgesics Anti-inflammatory Drugs and Antipyretics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/04972.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Infliximab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; I &gt; IN</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D2261.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Infliximab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; I</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_128234">INFLIXIMAB</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i991.htm" title="Go to appendix 1">Infliximab</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">see under <a title="BNF:target-block: Infliximab-arthritis" href="202659.htm#_208118">Cytokine Modulators</a> above; inflammatory bowel
disease (<a title="BNF:monograph: INFLIXIMAB" href="128211.htm#_128211">section 1.5.3</a>); psoriasis (<a title="BNF:monograph: INFLIXIMAB" href="201653.htm#_201653">section 13.5.3</a>)</p></div><div class="cAF" id="_128234.1"><h2>Cautions</h2> <p class="cAF">predisposition to infection; monitor for infection before, during, and for 6 months after treatment (see also Tuberculosis below); discontinue if new serious
infection develops; hepatitis B virus—monitor
for active infection; mild heart failure
(discontinue if symptoms develop or worsen); demyelinating disorders (risk of exacerbation); history or development of malignancy; history of prolonged immunosuppressant or PUVA treatment in patients
with psoriasis; <b>interactions:</b> Appendix
1 (infliximab) </p><div class="cAV"><h3>Tuberculosis</h3> <p class="cAX">Patients should be evaluated for
tuberculosis before treatment. Active tuberculosis should
be treated with standard treatment (<a title="sub-section: Antituberculous drugs" href="3899.htm#_3899">section 5.1.9</a>) for at least 2 months before
starting infliximab. Patients who have previously received
adequate treatment for tuberculosis can start infliximab but should
be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not
treated adequately, chemoprophylaxis should ideally be completed before
starting infliximab. In patients at high
risk of tuberculosis who cannot be assessed by tuberculin skin test,
chemoprophylaxis can be given concurrently with infliximab. Patients should be advised to seek medical attention
if symptoms suggestive of tuberculosis (e.g. persistent cough, weight
loss, and fever) develop</p></div><div class="cAV"><h3>Blood disorders</h3> <p class="cAX">Patients should be
advised to seek medical attention if symptoms suggestive of blood
disorders (such as fever, sore throat, bruising, or bleeding) develop</p></div><div class="cAV"><h3>Hypersensitivity reactions</h3> <p class="cAX">Hypersensitivity reactions
(including fever, chest pain, hypotension, hypertension, dyspnoea,
transient visual loss, pruritus, urticaria, serum sickness-like reactions,
angioedema, anaphylaxis) reported during or within 1–2 hours after
infusion (risk greatest during first or second infusion or in patients
who discontinue other immunosuppressants). All patients should be observed carefully for 1–2 hours after infusion
and resuscitation equipment should be available for immediate use.
Prophylactic antipyretics, antihistamines, or <span>hydrocortisone</span> may be administered. Monitor for symptoms of delayed hypersensitivity
if readministered after a prolonged period. Patients
should be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity
develop</p></div></div><div class="cAF" id="_128234.2"><h2>Contra-indications</h2> <p class="cAF">severe infections (see also under Cautions); moderate or severe heart failure</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">use only if essential; manufacturer advises adequate
contraception during and for at least 6 months after last dose</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">amount probably too small to be harmful</p></div><div class="cAF" id="_128234.3"><h2>Side-effects</h2> <p class="cAF">see under <a title="BNF:target-block: Cytokine inhibitor side-effects notes 10.1.3" href="202659.htm#_200785">Cytokine Modulators</a> and under Cautions above; also constipation, diarrhoea, dyspepsia,
gastro-intestinal haemorrhage, gastro-oesophageal reflux, flushing,
hypotension, hypertension, palpitation, tachycardia, sleep disturbances,
dizziness, paraesthesia, hypoaesthesia, arthralgia, myalgia, epistaxis,
alopecia, rash, ecchymosis, hyperhydrosis, new onset or worsening
psoriasis, dry skin; <i>less commonly</i> hepatitis, cholecystitis,
intestinal perforation, pancreatitis, heart failure, arrhythmia, bradycardia,
syncope, peripheral ischaemia, pleurisy, pulmonary oedema, amnesia,
agitation, confusion, nervousness, neuropathy, seizures, vaginitis,
eye disorders, bullous eruption, cheilitis, seborrhoea, impaired healing,
rosacea, hyperkeratosis, abnormal skin pigmentation; <i>rarely</i> pericardial effusion, vasospasm, interstitial lung disease, leukaemia,
lymphoma, demyelinating disorders, Stevens-Johnson syndrome, toxic
epidermal necrolysis; <i>also reported</i> hepatic failure</p></div><div class="cAF"><h2>Dose</h2> <p class="cR"><span class="cU">By intravenous infusion</span>, rheumatoid
arthritis (in combination with methotrexate), <span class="cAK">adult</span> over 18 years, 3 mg/kg, repeated 2 weeks and 6 weeks after initial
infusion, then every 8 weeks; if response inadequate after 12 weeks,
dose may be increased in steps of 1.5 mg/kg every 8 weeks, up to max.
7.5 mg/kg every 8 weeks; alternatively, 3 mg/kg may be given every
4 weeks; discontinue if no response by 12 weeks of initial infusion
or after dose adjustment</p><p class="cS">Ankylosing spondylitis, <span class="cAK">adult</span> over 18 years, 5 mg/kg, repeated 2 weeks and 6 weeks after initial
infusion, then every 6–8 weeks; discontinue if no response by 6 weeks
of initial infusion</p><p class="cS">Psoriatic arthritis (in combination with <span>methotrexate</span>), <span class="cAK">adult</span> over 18 years, 5 mg/kg, repeated
2 weeks and 6 weeks after initial infusion, then every 8 weeks</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li class="jN" id="_128235" style="margin: 0 0 0 20px;"><h1 class="title">Remicade®<span> (<a href="appendix-112803-S.htm#m268">Schering-Plough</a>)</span> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Intravenous infusion</span>, powder for
reconstitution, <span>infliximab,</span> net price 100-mg vial
= £419.62. 
    Label:
    10, alert card, counselling, tuberculosis, blood disorders,
and hypersensitivity reactions</div></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="212247.htm">Previous: GOLIMUMAB</a> | <a class="top" href="128235.htm#">Top</a> | <a accesskey="]" href="129937.htm">Next: RITUXIMAB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>